Emergent BioSolutions Sees Unusually Large Options Volume (NYSE:EBS)

Emergent BioSolutions Inc. (NYSE:EBS) was the target of some unusual options trading activity on Wednesday. Stock investors bought 3,153 put options on the company. This represents an increase of 344% compared to the average daily volume of 710 put options.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Fidelis Capital Partners LLC purchased a new position in shares of Emergent BioSolutions in the first quarter valued at approximately $67,000. BNP Paribas Financial Markets raised its holdings in Emergent BioSolutions by 155.3% in the first quarter. BNP Paribas Financial Markets now owns 163,589 shares of the biopharmaceutical company’s stock valued at $414,000 after acquiring an additional 99,520 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Emergent BioSolutions in the first quarter valued at approximately $57,000. Assenagon Asset Management S.A. raised its holdings in Emergent BioSolutions by 0.6% in the first quarter. Assenagon Asset Management S.A. now owns 839,414 shares of the biopharmaceutical company’s stock valued at $2,124,000 after acquiring an additional 5,042 shares in the last quarter. Finally, SeaCrest Wealth Management LLC acquired a new stake in Emergent BioSolutions in the first quarter valued at approximately $243,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Benchmark reissued a “buy” rating and issued a $5.00 price objective on shares of Emergent BioSolutions in a report on Thursday, April 11th.

Emergent BioSolutions Trading Up 70.5 %

Shares of EBS stock opened at $3.29 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.04 and a quick ratio of 0.54. The firm has a market cap of $172.36 million, a PE ratio of -0.22 and a beta of 1.24. The company has a 50-day moving average of $2.46 and a two-hundred day moving average of $2.23. Emergent BioSolutions has a 1-year low of $1.42 and a 1-year high of $10.88.

Emergent BioSolutions (NYSE:EBS) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.59 earnings per share for the quarter, topping the consensus estimate of ($3.65) by $4.24. Emergent BioSolutions had a negative net margin of 72.11% and a negative return on equity of 37.35%. The company had revenue of $300.40 million during the quarter. During the same period last year, the business earned ($3.17) EPS.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.